Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 3217 Carcinoma, Non-Small-Cell Lung 2731 Breast Neoplasms 2553 Colorectal Neoplasms 1464 Prostatic Neoplasms 1310 Neoplasm Metastasis 1302 Multiple Myeloma 1112 Melanoma 1102 Ovarian Neoplasms 1006 Lung Neoplasms 946 Recurrence 924 Leukemia, Myeloid, Acute 878 Pancreatic Neoplasms 833 Lymphoma, Non-Hodgkin 767 Lymphoma 713 Stomach Neoplasms 693 Carcinoma, Renal Cell 661 Carcinoma, Hepatocellular 648 Leukemia, Lymphocytic, Chronic, B-Cell 560 Squamous Cell Carcinoma of Head and Neck 550 Lymphoma, Follicular 516 Head and Neck Neoplasms 491 Glioblastoma 473 Small Cell Lung Carcinoma 447 Lymphoma, Large B-Cell, Diffuse 440 Triple Negative Breast Neoplasms 436 Advanced Solid Tumors 433 Leukemia 426 Uterine Cervical Neoplasms 420 Urinary Bladder Neoplasms 405

Interventions

tremelimumab 1 durvalumab 1 Vinorelbine 1 Gemcitabine 1 Erlotinib Hydrochloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Non - Small Cell Lung Cancer NSCLC × Clear all

NCT02352948 2024-07-26

ARCTIC

AstraZeneca

Phase 3 Completed

597 enrolled 23 charts

Non - Small Cell Lung Cancer NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡